Boehringer Ingelheim, Zai Lab Team up for Dual DLL3 Therapy Study

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.The post Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study appeared first on Hospital Management.

Boehringer Ingelheim, Zai Lab team up for dual DLL3 therapy study

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.